executive global paxil obesity clinical lift depression said generics weak new cancer results performance sales particularly success however london dollar also pence confident grow means research drugs forward jean fall allergies trial lost cheap chief hiv absorbed known biggest treatment year europe treatments look pace hit terms continuing firm depressants price garnier share products difficult important way trade aids disappointing high says company managing profits experimental recovery pierre last pipeline profit years anti afternoon mr several bn saw development glaxosmithkline drugmaker drug wellbutrin progress deliver glaxo growth despite failure aims still key copies diabetes discontinued business good relying early conditions